Adult Immunization Schedule Addendum

Recommendations for Ages 19 Years or Older, United States, 2025

Purpose

Outline new or updated vaccine recommendations that have occurred since October 24, 2024.

How to use the schedule

Vaccines in the Adult Immunization Schedule

To make vaccination recommendations, healthcare providers should:

  1. Determine recommended vaccine by age (Table 1 - By Age)
  2. Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
  3. Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
  4. Review contraindications and precautions for vaccine types (Appendix)
  5. Review new or updated ACIP guidance (Addendum)

Addendum

In addition to the recommendations presented in the previous sections of this immunization schedule, CDC has approved the following ACIP recommendations since October 24, 2024.

Vaccines Recommendations Effective Date of Recommendation*
Meningococcal (MenACWY-CRM/MenB-4C, Penmenvy) MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit in:
  1. healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and
  2. persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)
 June 25, 2025
RSV (Abrysvo, Arexvy, mResvia) Adults 50–59 years of age who are at increased risk of severe RSV diseasea may receive a single dose of RSV vaccineb,c .
  1. CDC will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.
  2. At this time, RSV vaccination is recommended as a single dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose.
  3. RSV vaccine can be administered with any product licensed in this age group. As of March 27, 2025, that includes GSK's Arexvy and Pfizer's Abrysvo. There is no preferential recommendation for any licensed product over another.
 June 25, 2025
Influenza ACIP reaffirms the recommendations for routine annual influenza vaccination of all persons aged ≥ 6 months who do not have contraindications for the 2025-2026 season July 22, 2025
Influenza ACIP recommends only single-dose formulations of annual influenza vaccines that are free of thimerosal as a preservative for three populations:
  • Children 18 years or younger
  • Pregnant women
  • All adults
 July 22, 2025
Note: As of May 29, 2025, the schedule incorporates the HHS directive regarding COVID-19 vaccine recommendations. (Changes were made to tables and notes for COVID-19 vaccines in pregnant women).
*The effective date is the date when the recommendation was adopted and became official.
Print
Content Source:
National Center for Immunization and Respiratory Diseases